Stocks and Investing
Stocks and Investing
Thu, January 28, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, January 27, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Anupam Rama Downgraded (VIR) to Sell and Held Target at $30 on, Jan 27th, 2021
Anupam Rama of JP Morgan, Downgraded "Vir Biotechnology, Inc." (VIR) to Sell and Held Target at $30 on, Jan 27th, 2021.
Anupam has made no other calls on VIR in the last 4 months.
There are 2 other peers that have a rating on VIR. Out of the 2 peers that are also analyzing VIR, 0 agree with Anupam's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Anupam
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $125 on, Wednesday, January 20th, 2021
- Geoff Meacham of "B of A Securities" Initiated at Strong Buy and Held Target at $55 on, Monday, October 5th, 2020
Contributing Sources